常茂生物(00954.HK)盈警：预计中期净亏损2400万至2700万元

Core Viewpoint - Changmao Biological (00954.HK) expects to record a consolidated net loss attributable to shareholders of approximately RMB 24 million to RMB 27 million for the six months ending June 30, 2025, compared to a net loss of approximately RMB 18.786 million in the same period last year [1] Financial Performance Summary - The board believes that the financial performance during this period is primarily affected by two factors: (1) a decrease in sales revenue and gross profit due to declining product sales prices and intense market competition; and (2) an increase in interest expenses included in the consolidated income statement, resulting from a reduction in the amount of capitalized interest on qualifying assets [1]